Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Lexeo Therapeutics (NASDAQ:LXEO) with a $23 price target.
August 14, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Lexeo Therapeutics with a $23 price target.
The reaffirmation of a Buy rating and a $23 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100